ATJ
Advanced Therapies Journal

VOL.7 / ISSUE 24 / SUMMER 2025
Online ISSN: 2676-7236
DOI: 10.22034/atj.2025.539031.1016

OPEN ACCESS

Pages: 1-11 / Review Article / Submit: 18 July 2025 / Accepted: 16August 2025

Availablein: https://www.atjournal.ir

Personalized Medicine in Aging: Strategies and Specific Needs of Older Adults

Hafza Zubair [1,*]

[1] COMSATS University Islamabad, COMSATS University Islamabad, Pakistan.

Corresponding Author's E-mail: hafsazbzz@gmail.com.

Abstract:

Advanced Therapies has been held in high regard in geriatric care, especially as the world population continues to age and the question of management of diseases that are multi-morbid and chronic becomes more pronounced. Personalized medicine attempts to quantify this complexity by customizing medical intervention based on the individual specifics in order to maximize treatment efficacy and reduce side effects.

This review examines the recent growth of personalized medicine in the management of ageing populations and highlights the importance of patient individualized education plans to take into consideration age-associated physiological modifications, such as modified pharmacokinetics, diminished organ functioning, senescence of the immune system, as well as having transformed body composition. The impact of both genetic predispositions and the environment and lifestyle exposures on the course and response to treatment is also discussed.

In addition to pharmacological options, this review emphasizes the increasing role of modern therapies that include a new field of gene therapy and cell-based therapies, targeted biologics, and RNA-based therapeutics, which may be tailored with high specificity and minimal systemic side effects. These frontier treatments frequently informed by molecular and genomic profiling have the potential to revolutionize chronic-illness care in the elderly. Naturally, the review also describes major ethical, financial, and logistical impediments to implementation, data privacy, access, and monetary accessibility. Lastly, it gives recommendations on how to break these hindrances and ensure there is equitable delivery of personalized and advanced therapies in geriatric medicine.

Keywords: elderly care, pharmacogenomics, geriatric healthcare, individualized therapy, age-related diseases

Introduction

The scene of global demographics is changing dramatically as the percentage of people 65 years of age and above rises at unheard-of rates (1). Particularly as aging is strongly associated with an increased burden of chronic, non-communicative diseases, including cardiovascular diseases, type 2 diabetes, neurodegenerative conditions like Alzheimer's and Parkinson's disease, osteoporosis, and many types of cancer, this demographic change presents major

How to Cite this Article:
H. Zubair, " Personalized Medicine in Aging: Strategies and Specific Needs of Older Adultss", Advanced Therapies Journal. vol. 7, no. 24, pp. 1-11, 2025.

public health challenges. Many times requiring advanced, long-term medical management, these chronic diseases demand more exact, individualized treatment plans than one-size-fits-all solutions (2).

Sometimes referred to as precision medicine, personalized medicine (PM) uses a paradigm change in healthcare to try to fit medical treatment to the unique traits of every patient (3). Personalized medicine can deal with issues related to do with genetic makeup, epigenetic changes, metabolomic changes, environmental exposures, and lifestyle, including diet, exercise, and social determinants of health. It is expected that by overcoming general therapeutic strategies, PM will help to enhance the effectiveness of treatment, reduce side effects, and ultimately improve clinical outcomes (4).

The use of personalized medicine has been shown to yield some considerable positive effects in oncology and with rare genetic conditions in young patients; however, its use has not been fully exploited yet among older patients (5). The issue with old patients is that they pose specific challenges that make the adoption of individualized medicine difficult. These include age-related physiological changes such as reduced renal and hepatic functioning, altered pharmacokinetics and pharmacodynamics, being more prone to adverse drug reactions, frequent polypharmacy and multimorbidity (6). Additionally, the processes of providing tailored care among this group are complicated by the following factors: social and functional determinants, such as frailty, cognitive decline, inaccessibility of healthcare technologies, and the question of digital literacy (7).

Given these complications, it is imperative to assess how tailored personalized medicine can be to satisfy the particular needs of the aging population. Regarding geriatric care, this review aims to present a whole picture of the present state of tailored medicine. In this paper, we will review current strategies, innovations, and the most critical impediments-scientific, clinical, and ethical-that need to be overcome to best implement PM in older adults (8). This paper also seeks to highlight chances for advancing inclusive and efficient precision health interventions that fit an aging society by pointing out gaps in research and clinical practice.

Physiological Changes in Aging and Their Impact on Medical Care

Changes in Organ Function

Aside from a spectrum of physiological changes, aging affects the pharmacokinetics (absorption, distribution, metabolism, and excretion) and pharmacodynamics (drug action and efficacy) of drugs. Considering tailored medicine for senior citizens, these developments demand careful thought. Two of the most important organs in drug metabolism and clearance the kidneys and the liver—undergo functional decline with aging (9). Renal blood flow, lower glomerular filtration rate (GFR), and tubular function all help to progressively lower renal function. Among the drugs mostly eliminated by the kidneys whose excretion can be greatly lowered by these changes are digoxin, some antidiabetic medications, and aminoglycosides. In polypharmacy or dehydration, especially, poor renal clearance can lead to drug accumulation and increased nephrotoxicity risk (10). While less so than in renal function, hepatic function changes with age. Reduced liver mass, hepatic blood flow, and activity of metabolic enzymes especially those involved in phase I reactions e.g., cytochrome P450 enzymes can all lower lipophilic drug metabolic clearance. Extending the half-life of drugs and raising plasma drug concentrations will help to reduce toxicity and the risk of adverse drug reactions (ADRs) (11). Apart from pharmacokinetic considerations, aging changes pharmacodynamic reactions as well. Older people may show increased sensitivity to some drugs (e.g., benzodiazepines and opioids) while showing decreased responsiveness to some others (e.g., beta-adrenergic agonists). In order to be as safe and efficacious as possible, therapy should therefore be personalized to include personalized dosing, frequent evaluation, and consideration of age-related pharmacological parameters (12).

Beyond metabolism, aging produces immunosenescence a process whereby the immune system loses integrity. Taken together, these include compromised function of B cells, decreased production of naive T cells, and chronic low-grade inflammation (inflammaging), impairing the body's capacity to mount strong immune responses (13). The implications of these immune changes on the progression of infectious disease, the efficacy of vaccines and elderly control of chronic inflammatory disease are indeed strong. Personalized immunity may also be required by providing predesigned immunomodulators, adjuvanted vaccines, and personalized immunization schedules to enhance immunization protection to this vulnerable population (14).

Cognitive Decline

Another age-related determinant making the delivery of medical care to elderly people or sick individuals very difficult is cognitive deterioration. Older people are more prone to acquiring diseases, including mild cognitive impairment (MCI), Alzheimer's disease, and other dementias. The diseases are capable of significantly distorting the understanding, memory, and adherence capacity of a patient to complicated medical prescriptions (15). The ideas of personalized medicine hold that

cognitive decline calls for the application of unique treatments different from pharmacological drugs. Medication schedules could have to be streamlined to lower the cognitive load and the possibility of non-adherence. Care plans ask family members or caregivers to be involved in the decision-making process and incorporate digital health tools, pill organizers, or reminders (16). Furthermore affected by cognitive impairment could be a person's capacity to provide informed permission or to properly express symptoms. This presents major ethical questions regarding the autonomy and decisions taken by groups. Clinicians have to apply sensitive communication techniques; cognitive capacity has to be routinely assessed using reliable tools. By including neurocognitive profiles in tailored treatment plans, people can recognize those who are at risk and direct treatments meant to maintain cognitive capacity and improve general quality of life conditions (17). When all the elements are taken into account, cognitive and physiological changes experienced by senior citizens underline the need to customize medical treatment to the reality of the biological process of aging. A one-size-fits-all approach is inadequate to guarantee that treatments for the elderly population are both safe and effective. Functional assessments, geriatric syndromes, and comprehensive care planning have to be part of customized medicine (18).

Multi-Morbidity and Polypharmacy in Aging

Challenges of Multi-Morbidity

When people age, they often have Multi-morbidity, i.e. two or more chronic diseases, which complicates clinical care and increases the likelihood of poor outcomes. Older patients are more likely to have multimorbid conditions that include cardiovascular disease, diabetes, arthritis, neurodegenerative disease and chronic kidney disease, which adds to a more complex treatment situation (19). The complex management of these diseases often leads to polypharmacy, or taking multiple medications, which may lead to an increased rate of drug-drug/drug-disease interactions and adverse drug reactions and struggles with medication adherence. These risks are further increased by age, consisting of physiological changes such as impaired renal and hepatic function, changes therein affecting drug metabolism, and the residual physical reserve, all of which affect the responsiveness of the body to pharmacologic treatment (20). Guidelines of conventional treatment tend to be disease-specific and are usually based on the studies of younger or 1-disease patients, and they can be ineffective in older adults with multimorbidity. Personalized medicine brings a more appropriate or adapted solution in this regard. Personalized medicine overcomes these shortcomings of standardized care by designing treatment approaches on an individual basis, according to a person's genetic, clinical, and psychosocial characteristics (21). In personalized medicine, pharmacogenomics is a tool that helps clinicians select and dose drugs optimally using the genomic profile of a patient to achieve better therapeutic outcomes and minimize adverse effects. As an example, drug metabolism typically varies in individuals with genetic variants in cytochrome P450 genes or other drug transporters, and the identification of these variants can guide personalization of therapy and help inform the need to prescribe a drug. In addition, the ability to incorporate real world data, clinical decision support tools, and electronic health records enables active, patient-specific care planning where comorbidities and historic responses to treatment are considered (22). Despite these promising developments, barriers such as limited access to genetic testing, insufficient provider education, and ethical concerns regarding data privacy must be addressed to fully realize the benefits of personalized medicine in older adults. Finally, the fifth step of treatment multi-morbidity in elderly patients should be based on the removal of the disease-based model in favor of the patient-based model of precision medicine that can provide a better therapeutic outcome and patient well-being (23).

Pharmacogenomics and Aging

Included in the personalised medicine is pharmacogenomics, which deals with studying how genes interact with drugs to have a response in a person. In the elderly, pharmacogenomic data can be utilized to deduce how a patient is likely to catabolize particular medicines and limit the chances of adverse effects (24). As an example, genetic differences in other enzymes, such as cytochrome P450 (CYP450), can affect the way some medications, such as anticlotting medications and antidiabetic drugs, are broken down. Introduction of pharmacogenomic testing in clinical practice can enable healthcare providers to develop safer and more effective treatment regimens, which have many benefits for older adults (25).

Genomic and Environmental Factors in Aging

Genetic Influences on Aging and Disease

Genetic factors have a key role in the biological process of aging and also age-related diseases, and are involved in population variability in both health trajectories and longevity. Many genes have been discovered to regulate longevity, cellular senescence, and the predisposition to age-dependent diseases like cardiovascular, cancer, and neurodegenerative diseases (26). The recent developments in genomics have helped scientists to identify the genetic

variations that moderate inflammation, oxidative stress response, and DNA repair pathways, which have been consistently tied to changes in the age of physiological decline. In the midst of personalized medicine, these findings have a significant implication on the care of the elderly (27). Genetic screening is becoming more common to distinguish high-risk patients with a given disease in order to effectively find more personalized prevention methods. The example of the APOE ε4 single-nucleotide polymorphism is a well-described genetic risk factor in the development of Alzheimer's disease, and those who possess this particular variant are potential candidates to benefit through early cognitive screening, lifestyle changes and possible participation in clinical trials as subject to receive disease-modifying treatment (28). Similarly, hereditary cancer-related genes, e.g. BRCA1 and BRCA2, can considerably elevate the risk of breast, ovarian and other cancers over a lifetime, which necessitates genetic testing to inform decisions regarding following up the disease (increased surveillance), prophylactic surgery, or chemoprevention. Along with risk prediction, genetic data can enhance treatment personalization; polymorphisms in drug-metabolizing enzymes, so common in older individuals, can alter a person's response to common drugs used in older age groups, thereby personalizing drug selection and dosing (29). Ethical considerations, the psychological burden of genetic risk disclosure, and patient access disparities are some of the concerns that are relevant to genetic information implementation in clinical practice, although they are still considered to be great promises. Nonetheless, the trend towards the uses of genomic technologies in geriatrics will presumably lead to an increasingly preventive and remedial approach to the healthy aging process and increasing the healthy years of life (30).

Environmental and Lifestyle Factors

Environmental and lifestyle factors have a significant negative effect on the aging process and the condition of the development of chronic morbidity, which has a complementary relationship with genetic determinants. The factors that have a large influence on health and the pathway towards longevity include diet, physical activity, smoking, and alcohol consumption, sleep quality, as well as long-term exposure to environmental toxins (e.g. air pollution, heavy metals and endocrine-disrupting chemicals). The aggregate effects of these external influences are magnified as people age, resulting in oxidative stress, chronic inflammation, cell injury and accelerated aging (31).

Genetically personalized medicine will use individualized care approaches by incorporating these potentially variable factors, including lifestyle and the environment, that can interact with genetic susceptibilities in ways that can increase or eliminate disease risks (32). Another example is the individual with a genetic tendency to type 2 diabetes who can be helped by intense, individualized nutrition, coupled with routine workouts and weight control, and so prevent or at least postpone a disease development. Similarly, patients who have cardiovascular risk factors may be advised to make lifestyle modifications that would be tailored to their clinical phenotypes but also to their genomes, once personalized to interventions that relate to the reduction of sodium or increasing physical activity and smoking cessation (33).

With the rise of wearables, mobile healthcare software, and various forms of digital biomarkers, the real-time tracking of lifestyle-related factors is made possible, and the adaptation of health plans can be adjusted in real-time. Furthermore, the epigenetics studies have shown that the effects of environmental as well as behavioral factors can also manipulate the gene expression through the influencing of both methylation and modifications of histones and have proved that the aging process is not irreversible, but depending on the available interventions, the aging process can also be suspended or at least stopped partly by the effect of the interventions (34). The development of such things as wearable devices, mobile health applications, and digital biomarkers helps to introduce real-time tracking of lifestyle parameters, providing an opportunity to alter health plans, based on instant feedback (35). Epigenetic studies have been found to demonstrate that behavior and environmental factors can affect gene expression via processes like DNA methylation and histone regulation, and have also indicated that the aging process is not irreversible and could be reversed or at least slowed down through a series of interventions (36).

Integrating the role of the environment and lifestyle into the concept of personalized medicine, clinicians can create a more wholesome, preventive, and therapeutic strategy of care that would not be limited to symptom management by actively enhancing the resilience, functional independence, and overall well-being of aging people. Such a strategy not only results in a longer lifespan but also a healthier life, in the number of years free of disability and illness (37).

Emerging Technologies in Personalized Medicine for Older Adults

Artificial Intelligence and Machine Learning

Artificial intelligence (AI) and machine learning (ML) have now become revolutionary in the field of personalized medicine as they provide sources to tackle the complexity of healthcare in aging populations (38). Since older adults typically have

a complex mixture of concerns (chronic conditions, cognitive decline, and functional limitations), AI-enabled tools can be indispensable in using a variety of data (genomic, clinical, imaging, behavioral and environmental data) and translating this information into useful feedback. Big and complicated data can be processed by these technologies, and correlations, patterns, and trends are detected that cannot be cognitively perceived by a human (39).

In geriatric practice, AI-driven algorithms are being used to assist in making more accurate diagnoses, making therapy choices, and keeping track of disease. As an example, the use of machine learning models has demonstrated potential in forecasting the onset and progression of diseases like Alzheimer's and Parkinson's based on longitudinal changes in biomarkers (e.g., in imaging, genetic risk factors, such as the APOE variants), cognitive tests, and potentially lifestyle behaviors (40). Such predictive models can also be used to help select interventions and the timing of those interventions to maximize the benefits and prolong the maintenance of cognitive function (41).

The use of IA also enables risk stratification of the older population to assess individuals who are susceptible to adverse drug reactions, readmission and functional decay. The integration of pharmacogenomic information would allow AI to guide clinicians in optimizing drug regimens in order to avoid complications related to polypharmacy, commonly faced by geriatric patients (42). Further, NLP tools can draw meaningful insights that might have otherwise been identified by aggregating unstructured EHRs to help healthcare providers develop comprehensive and personalized care plans. In addition to diagnostics and treatment planning, AI-assisted wearable devices and intelligent appliances provide 24/7 monitoring of vital signs, mobility trackers, sleep quality and drug compliance status (43). By allowing health deterioration to be identified early to assist in aging in place, these tools can help prevent hospitalizations. The use of AI enhances the decision support systems, which also empowers clinicians and caregivers who, through evidence-based recommendations, receive advice that considers the specific physiological and psychosocial situation of a patient among the elderly (44).

Nevertheless, the ethical, privacy, and equity consequences are issues of concern to the widespread use of AI and ML in geriatric personalized medicine, since even the most optimistic scenarios (45). Algorithmic transparency, overcoming biases in training data, and data security are crucial to prevent the absence of trust and promote fair and equitable provision of care. Even so, these technologies have the potential to transform the process of aging care by making personalized medicine more proactive, precise, and patient-centered as they continue to evolve (46).

Biomarkers and Personalized Diagnostics

Personalized diagnostics hinges on biomarkers as measurable indicators of bio-status or pathological processes, especially with age-related dimensions. With the swelling population of the aging people, there is a need for early, accurate and more individualized forms of disease detection and management. In geriatric medicine, biomarkers provide an effective means of predicting the onset of disease, tracking disease progression and even evaluating the effectiveness of treatment in many cases before the clinical pathology is noticed (47).

Age-related alterations at the molecular and cellular levels (e.g., chronic, low-grade inflammation, or inflammagin, oxidative stress, or cell senescence) are often mirrored by certain biomarker patterns. Discovering and confirming these biomarkers can be used in early diagnosis of disease conditions, especially cardiovascular disease, chronic kidney disease, diabetes type two, Osteoporosis and diseases of the nerve like Alzheimer's and Parkinson among others (48). As an example, cardiac biomarkers, e.g. high-sensitivity troponin and natriuretic peptides (e.g. NT-proBNP) can provide helpful information regarding the subclinical heart failure or strain in elderly individuals. Equally, biomarkers such as serum creatinine, cystatin C, and albumin-to-creatinine ratio kidney data allow clinicians to identify and treat early renal impairment that is prevalent in older individuals (49).

In the neurodegenerative disease field, the existing activity of the measurement of neural biological fluids (cerebral spinal fluid (CSF) and plasma) biomarkers has transformed early diagnosis of Alzheimer's disease, which includes measurements of 8-amyloid protein, frontotemporal dementia, total tau, and phosphorylated tau proteins. Such biomarkers can be used to stratify which individuals at risk of dementia can be treated years or even decades before their clinical onset, to the benefit of effective interventions to prevent the disease or even cure it (50).

Tailoring of diagnostics and interventions to the disease, as well as to the biological age of the patient (which often significantly differs from chronological age), is enabled by the personalization of diagnostics on the basis of a biomarker profile. This differentiation is vital because some people will undergo a faster rate of biological aging because of genetic tendencies, environmental exposures or lifestyle behaviors. Biomarker-aided interventions have the potential to tailor choices on whether, when, and how aggressively therapeutic interventions are initiated, and what the interventions should be in

patients with multimorbidity and many medications (51).

Additionally, personalized diagnostics can further be enhanced by incorporating biomarker evidence along with the evidence of genomic, proteomic, metabolomic, and microbiomic data sources, so-called multimics. This kind of merger makes it possible to understand the health status and disease development of an individual in its whole dimension, and it creates opportunities regarding the provision of preventive geriatric health care (52).

Nevertheless, there are still issues with validation and standardization of discovery and routine use of biomarkers in older adults. Too much variability due to comorbidities, use of medication, and other age-related physiological changes makes interpretation difficult. Hence, further research, universal longitudinal studies and age-specific reference ranges are mandatory to leverage the clinical usefulness of biomarkers in geriatric personalized medicine (53).

Barriers to Implementing Personalized Medicine in Geriatric Care

Economic Barriers

Besides financial barriers, economic barriers are also a major threat to the wider adoption of personalized medicine, especially in the care of the aged. Personalized medicine may run on very advanced technology, including genetic/genomic testing, enhanced biomarker analysis and high-resolution imaging systems, and tailored medication - all of which can advance much too costly to be affordable (54). A substantial financial burden can be imposed on healthcare systems by the costs of such relative diagnostic tools and individual treatment options, especially when budgets are already strained or costs are not covered in low- and middle-income countries (55).

In case of older adults, who more often than not need complex, long-term medical treatment of their chronic conditions and multimorbidity, the personalized interventions increase the cost of care even more (56). Genetic testing or precision therapies may be beyond the current means of many elderly patients, who base their income on fixed payments, pensions, or coverage with limited insurance plans. Such an economic inequality generates health inequalities in access to personalized medicine, constituting a possible way of worsening the current health inequalities in older populations (57).

Personalized medicine is variably covered by insurance across the world. Genetic screening, pharmacogenomic testing, and novel genetically targeted treatment have also not seen full recognition or reimbursement by health insurance policies or governmental health programs in many regions, with a resulting lack of access to individuals who could benefit the most. Without universal coverage, financial burdens are placed on patients and families, discouraging usage and reducing the potential value of personalized medicine to geriatrics in general (58).

Also, the support structure that would enable the implementation of personalized medicine (i.e., trained workforce, bioinformatics support, and genetic counseling services) would add further costs to the existing infrastructures that are not ready to take the load. The economic limitations can also act as a restrictive factor, leading to slower adoption of new innovative technologies into the mainstream of clinical practice, increasing the time lag between the technology options and their positive impact on older adults (59).

To overcome these economic impediments, it is important that policy makers, medical professionals, insurance companies and industry stakeholders act in sync with each other. Some of the most critical strategies that should be implemented are the development of cost-effectiveness analyses, support of policy changes to increase insurance coverage, investment in scalable and affordable diagnostic technology, and investment in resource distribution on an equal basis (60). Moreover, creative approaches such as public-private partnerships and novel funding mechanisms can be valuable in minimizing the cost of personalized medicine and thereby improving equitable accessibility so that the benefits of personalized medicine are available to all older adults, irrespective of their socioeconomic status (61).

Ethical and Social Considerations

The use of personalized medicine in aging populations has many ethical and social implications that are complex and must be carefully considered because the proper interpretations of the process must pursue fairness and responsible healthcare service. Among the central ethical issues, there is the concern over privacy and confidentiality of the genetic information (62). Genetic data is also very sensitive in nature as it holds deep personal and possibly predictive information concerning the health risks and predispositions in an individual. In the case of older adults, the security of this data being stored properly, where no one other than the owner can access it, is a key to the trust of healthcare systems. The disclosures of genetic privacy may give rise to stigmatization or abuse of the information, which presents patients with worries about who gets to see their record and can do with it (63).

The other major ethical concern is the prospect of genetic discrimination, especially in matters of insurance coverage, workplaces, and social relations. Older people may even be subject to prejudices or to being denied services if their genetic predisposition

towards specific diseases is revealed, irrespective of legislation in some nations intended to stop this form of discrimination. There are dangers that individuals fear discrimination due to the results of genetic tests, which makes them avoid genetic testing and the implementation of personalized medicine altogether (64).

Informed consent is another issue that is related to geriatric care, especially when the patient has cognitive decline or dementia. The correct procedure of consenting to genetic testing and other complex personalized interventions should be sensitively explained, and discussion with custodians or legal guardians should be conducted in order to make valid and informed consent. It is crucial that older adults be aware of the consequences, risks, and benefits of the testing to stay as autonomous and free citizens (65).

Personalization medicine in the older populations is significantly affected by social determinants of health as well. Genetic information can increase confusion around the mechanisms of health literacy, and some older adults have low health literacy due to a lack of access or ability to navigate the healthcare system and make informed health choices. Personalized medicine demands the absence of unclear education and support sensitivity to the level of understanding of the individual person to prevent the enhancement of the health disparities (66).

Another burning issue is accessibility. The socioeconomic status, the geographical location and the culture of an older person have been seen as having some role to play in terms of the accessibility of the older person to the customized diagnostic, treatments and post-testing measures. There also may be additional barriers to genetic counseling or new medical treatments among rural populations or marginalized groups, further widening health disparities (67).

To mitigate these ethical and social issues, the policies and healthcare practitioners should employ inclusive approaches that encourage transparency, education and equality. This encompasses drafting the laws of the genetic data protection, laws of anti-discrimination, culturally competent communication, health literacy programs in older aging, among others (68). Moreover, it is important to promote community involvement and help older adults make decisions to make this group of patients more empowered and able to enjoy personalized medicine delivered to them (69).

In short, ethical stewardship and social sensitivity should also become essential to realize the full promise of personalized medicine in aging populations by ensuring it adds value to each person, is reached in equitable and ethical ways, and addresses all in a way that respects their dignity, rights, and diverse backgrounds (70).

Logistical Challenges

The barriers that present challenges to older adults are usually in the form of dire logistical problems to access personalized medicine. Their lack of mobility, such as the ability to drive or indeed rely on others to take them to their medical appointments, as well as to specialized testing to receive specialized care, usually becomes their disability to attend regular medical care or indeed, testing so that they can receive specialized care (71). Cognitive dysfunctions that are common in an aging-growth community, like memory loss and impaired executive functioning, have the potential to make interaction with medical institutions, reading complex medical information, and adhering to medical prescriptions much more difficult. Communication barriers that can be augmented are sensory deprivation, such as loss of sight or hearing ability. Healthcare systems and providers must develop more adaptable models that are more patient-centric to deal with such issues (72). This can be in terms of offering transport assistance, application of telemedicine and home-based care comparisons, simplification of language usage or reducing the complexity of the language, and the involvement of caregivers in treatment modality. It can address these logistical challenges keenly, and by default, personalized medicine would become effective for older adults and ultimately give them good positive results in their health and other aspects of life (73).

Future Directions in Personalized Medicine for Aging Populations

The future of health is personalized medicine, and this has a fascinating potential for bettering the lives and the outcome in older adults. The future research directions in genomic medicine, AI, and even more personal approaches to diagnostics are predicted to enable us to predict, prevent, and treat age-related diseases and individualize the process (74). However, navigating the economic, ethical, and practical challenges would require the interaction of the healthcare providers with the researchers, policymakers, and above all, the aging population. It is necessary to incorporate personalized medicine into the everyday life of geriatrics in order to provide the elderly with the most beneficial level of care by taking into consideration their own needs (75).

DISCUSSION

This review emphasis the fact that although the conceptual requirement of personalized medicine has grown considerably during the last two decades, it is still in a nascent and fragmented stage as applied intermittently to geriatric medicine (76). The gap is not only technical but also epistemological: most studies on pharmacogenomic finding and

biomarker validation were studied in a younger or disease-specific group with limited extension into the physiological complexity of elderly populations (77). As such, there is a danger in overpromising the benefits, without providing adequate consideration to the altered pharmacokinetics, multimorbidity, and frailty for which this group is characterized (78).

One principal constraint from the current pool of evidence is a lack of robust, large, age-stratified clinical trials. Although a number of genetic variants and biomarkers have been associated with drug response in elderly subpopulations, reproducibility across different populations is inconsistent (79). The fact that surrogate endpoints are relied on instead of patient hard clinical outcomes, further undermines their immediate applicability in clinical decision-making. This underpins a critical need to refocus research priorities, past descriptive studies and towards pragmatic, geriatric-focused trials that can assess efficacy and tolerability in a real world multi-morbid context (80).

Technological innovations - especially artificial intelligence, machine learning and monitoring using wearable technology - have been touted as the solution to geriatric care's complexities (81). However, these approaches can hauntingly increase health inequities if digital literacy, socioeconomic disparities and cognitive decline are not explicitly considered in designing and implementing strategies. Algorithmic transparency and the removal of bias in training datasets are other imperatives if these toolsets are to be trusted by clinicians and patients (82).

Advanced therapies like gene and cell-based therapy mark the cutting edge of individualized treatment but have enormous translational hurdles. The high financial investment, the logistic challenges and inferentiability of ancillary clinical studies within the elderly population preclude, at this time, their general incorporation in routine practice (83). In contrast, strategies that are more immediately actionable-ones that can singly be described as pharmacogenomic-guided prescribing, dose optimization based on renal and hepatic function, and risk stratification by polypharmacy-found realistic opportunities for near-term impact (84). Policymakers and healthcare systems should therefore try to focus on scalable and cost-effective ways to take advantage of personalization while ensuring at the same time that regulatory and ethical structures are prepared to cope with the next-generation therapeutics (85).

In conclusion, the promise of personalized and advanced therapies for older adults is undeniable, but their successful implementation requires a paradigm shift in research, practice, and policy. Establishing geriatric centered clinical evidence, equitable access to digital and molecular innovations andcrafting the divide between technological enthusiasm and pragmatic delivery of health care will determine whether precision medicine will become a transformational tool or just an aspirational dream for aging societies at risk.

CONCLUSION

Personalized medicine is an innovative strategy in healthcare that can be used to change the way age-related conditions are treated in a far better way. Based on the individual physiological, genetic, and environmental conditions that age-related changes affect health in later years, personalized medicine would assist in streamlining the approach to treatment, minimizing adverse effects, and increasing the quality of life in general. The introduction of PM to geriatric care offers a variety of obstacles that need to be resolved to ensure a positive outcome, including economic, moral, and logistical challenges. Personalized medicine has a chance to become a landmark in the realm of aging-related healthcare with constant research and innovation to help people and provide them with what they need.

Authors' Contribution

The author read and confirmed the final manuscript.

Funding

Not applicable.

Availability of data and materials

All data are obtainable after an appeal from the corresponding author.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

REFERENCE

1. Noto, S., Perspectives on Aging and Quality of Life. Healthcare (Basel), 2023. 11(15).
2. Kopp, W., Aging and "Age-Related" Diseases - What Is the Relation? Aging Dis, 2024. 16(3): p. 1316-1346.
3. Stefanicka-Wojtas, D. and D. Kurpas, Personalised Medicine-Implementation to the Healthcare System in Europe (Focus Group Discussions). J Pers Med, 2023. 13(3).
4. Gupta, I., et al., Connecting the dots: investigating the link between environmental, genetic, and epigenetic influences in metabolomic alterations in oral squamous cell carcinoma. Journal of Experimental & Clinical Cancer Research, 2024. 43(1): p. 239.
5. Wang, R.C. and Z. Wang, Precision Medicine:

Disease Subtyping and Tailored Treatment. Cancers (Basel), 2023. 15(15).
6. Wang, R.C. and Z. Wang Precision Medicine: Disease Subtyping and Tailored Treatment. Cancers, 2023. 15, DOI: 10.3390/cancers15153837.
7. Reynolds, C.F., 3rd, et al., Mental health care for older adults: recent advances and new directions in clinical practice and research. World Psychiatry, 2022. 21(3): p. 336-363.
8. Edvardsson, M. and M.K. Heenkenda, Precision Medicine: Personalizing Healthcare by Bridging Aging, Genetics, and Global Diversity. Healthcare (Basel), 2025. 13(13).
9. Ngcobo, N.N., Influence of Ageing on the Pharmacodynamics and Pharmacokinetics of Chronically Administered Medicines in Geriatric Patients: A Review. Clin Pharmacokinet, 2025. 64(3): p. 335-367.
10. Reynolds 3rd, C.F., et al., Mental health care for older adults: recent advances and new directions in clinical practice and research. World Psychiatry, 2022. 21(3): p. 336-363.
11. Ruiz, A. and S. DiCristina, Absorption to Excretion: The Aging Body's Take on Drugs – A Review of Pharmacokinetic Changes and their Impact on Medication Management. Current Pharmacology Reports, 2025. 11(1): p. 42.
12. Gronich, N., Central Nervous System Medications: Pharmacokinetic and Pharmacodynamic Considerations for Older Adults. Drugs Aging, 2024. 41(6): p. 507-519.
13. Wang, Y., et al., Immunosenescence, aging and successful aging. Front Immunol, 2022. 13: p. 942796.
14. Müller, L. and S. Di Benedetto Immunosenescence and Cytomegalovirus: Exploring Their Connection in the Context of Aging, Health, and Disease. International Journal of Molecular Sciences, 2024. 25, DOI: 10.3390/ijms25020753.
15. Chen, L., J. Jiao, and Y. Zhang, Therapeutic approaches for improving cognitive function in the aging brain. Front Neurosci, 2022. 16: p. 1060556.
16. Haleem, A. and M. Javaid, Role of cognitive computing in enhancing innovative healthcare solutions. Advances in Biomarker Sciences and Technology, 2024. 6: p. 152-165.
17. David, M.C.B., et al., Considerations for legal, ethical, and effective practice in dementia research. Brain Commun, 2024. 6(4): p. fcae211.
18. Barbaccia, V., et al., Mature and Older Adults' Perception of Active Ageing and the Need for Supporting Services: Insights from a Qualitative Study. Int J Environ Res Public Health, 2022. 19(13).
19. Skou, S.T., et al., Multimorbidity. Nat Rev Dis Primers, 2022. 8(1): p. 48.
20. Sutanto, H., Tackling polypharmacy in geriatric patients: Is increasing physicians' awareness adequate? Archives of Gerontology and Geriatrics Plus, 2025. 2(3): p. 100185.
21. Rushforth, A. and T. Greenhalgh, Personalized Medicine, Disruptive Innovation, and "Trailblazer" Guidelines: Case Study and Theorization of an Unsuccessful Change Effort. The Milbank Quarterly, 2020. 98(2): p. 581-617.
22. Sadee, W., et al., Pharmacogenomics: Driving Personalized Medicine. Pharmacol Rev, 2023. 75(4): p. 789-814.
23. Erdmann, A., C. Rehmann-Sutter, and C. Bozzaro, Patients' and professionals' views related to ethical issues in precision medicine: a mixed research synthesis. BMC Med Ethics, 2021. 22(1): p. 116.
24. Auwerx, C., et al., From pharmacogenetics to pharmaco-omics: Milestones and future directions. HGG Adv, 2022. 3(2): p. 100100.
25. Zhang, Y., et al., CYP3A4 and CYP3A5: the crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms. PeerJ, 2024. 12: p. e18636.
26. Castruita, P.A., et al., Genetic, Social, and Lifestyle Drivers of Healthy Aging and Longevity. Curr Genet Med Rep, 2022. 10(3): p. 25-34.
27. Zhao, Y., et al., DNA damage and repair in age-related inflammation. Nat Rev Immunol, 2023. 23(2): p. 75-89.
28. Stocker, H., et al., Prediction of clinical diagnosis of Alzheimer's disease, vascular, mixed, and all-cause dementia by a polygenic risk score and APOE status in a community-based cohort prospectively followed over 17 years. Molecular Psychiatry, 2021. 26(10): p. 5812-5822.
29. McCarthy, A.M. and K. Armstrong, The role of testing for BRCA1 and BRCA2 mutations in cancer prevention. JAMA Intern Med, 2014. 174(7): p. 1023-4.
30. Jamal, L., W. Schupmann, and B.E. Berkman, An ethical framework for genetic counseling in the genomic era. J Genet Couns, 2020. 29(5): p. 718-727.
31. Argentieri, M.A., et al., Integrating the environmental and genetic architectures of aging and mortality. Nature Medicine, 2025. 31(3): p. 1016-1025.
32. Molla, G. and M. Bitew, Revolutionizing Personalized Medicine: Synergy with Multi-Omics Data Generation, Main Hurdles, and Future Perspectives. Biomedicines, 2024. 12(12).
33. Singh, S., et al., Deciphering the complex interplay of risk factors in type 2 diabetes mellitus: A comprehensive review. Metabolism Open, 2024. 22: p. 100287.
34. Thacharodi, A., et al., Revolutionizing healthcare and medicine: The impact of modern technologies for a healthier future-A comprehensive review.

Health Care Sci, 2024. 3(5): p. 329-349.
35.Ahmed, M.M., et al., Integrating Digital Health Innovations to Achieve Universal Health Coverage: Promoting Health Outcomes and Quality Through Global Public Health Equity. Healthcare (Basel), 2025. 13(9).
36.Smokovski, I., et al., Digital biomarkers: 3PM approach revolutionizing chronic disease management - EPMA 2024 position. Epma j, 2024. 15(2): p. 149-162.
37.Alzeer, J.J.J.o.P.H. and Emergency, Integrating medicine with lifestyle for personalized and holistic healthcare. 2023, 2023. 7.
38.Bajwa, J., et al., Artificial intelligence in healthcare: transforming the practice of medicine. Future Healthc J, 2021. 8(2): p. e188-e194.
39.Alowais, S.A., et al., Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Medical Education, 2023. 23(1): p. 689.
40.Wang, H., et al., Neurodegenerative disorders: A Holistic study of the explainable artificial intelligence applications. Engineering Applications of Artificial Intelligence, 2025. 153: p. 110752.
41.Alowais, S.A., et al., Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Med Educ, 2023. 23(1): p. 689.
42.Alsanosi, S.M. and S. Padmanabhan, Potential Applications of Artificial Intelligence (AI) in Managing Polypharmacy in Saudi Arabia: A Narrative Review. Healthcare (Basel), 2024. 12(7).
43.Baig, M.M., et al. Generative AI in Improving Personalized Patient Care Plans: Opportunities and Barriers Towards Its Wider Adoption. Applied Sciences, 2024. 14, DOI: 10.3390/app142310899.
44.Dailah, H.G., et al., Artificial Intelligence in Nursing: Technological Benefits to Nurse's Mental Health and Patient Care Quality. Healthcare (Basel), 2024. 12(24).
45.Farhud, D.D. and S. Zokaei, Ethical Issues of Artificial Intelligence in Medicine and Healthcare. Iran J Public Health, 2021. 50(11): p. i-v.
46.Williamson, S.M. and V. Prybutok Balancing Privacy and Progress: A Review of Privacy Challenges, Systemic Oversight, and Patient Perceptions in AI-Driven Healthcare. Applied Sciences, 2024. 14, DOI: 10.3390/app14020675.
47.Bodaghi, A., N. Fattahi, and A. Ramazani, Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases. Heliyon, 2023. 9(2): p. e13323.
48.Rea, I.M., et al., Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines. Front Immunol, 2018. 9: p. 586.
49.Vasan, S.K., et al., Utility of Cardiac Biomarkers (N-Terminal Pro-B-Type Natriuretic Peptide and Hs-Troponin-T) in Predicting Mortality, Cardiovascular, and Renal Outcomes in Patients with Chronic Kidney Disease. Am J Nephrol, 2025: p. 1-16.
50.Kang, J.H., et al., Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology. Clin Chem, 2023. 69(11): p. 1247-1259.
51.Tao, X., et al., Biomarkers of Aging and Relevant Evaluation Techniques: A Comprehensive Review. Aging Dis, 2024. 15(3): p. 977-1005.
52.Babu, M. and M. Snyder, Multi-Omics Profiling for Health. Mol Cell Proteomics, 2023. 22(6): p. 100561.
53.Loughlin, K.N.M., et al., Perspective: Biomarkers of Aging in Human Nutrition Research—A Focus on Applications, Challenges, and Opportunities. Advances in Nutrition, 2025: p. 100486.
54.Parekh, A.E., et al., Artificial intelligence (AI) in personalized medicine: AI-generated personalized therapy regimens based on genetic and medical history: short communication. Ann Med Surg (Lond), 2023. 85(11): p. 5831-5833.
55.Butt, M.D., et al., A systematic review of the economic burden of diabetes mellitus: contrasting perspectives from high and low middle-income countries. J Pharm Policy Pract, 2024. 17(1): p. 2322107.
56.Wu, J., et al., Healthcare for Older Adults with Multimorbidity: A Scoping Review of Reviews. Clin Interv Aging, 2023. 18: p. 1723-1735.
57.Barajas-Nava, L.A., et al., Models of comprehensive care for older persons with chronic diseases: a systematic review with a focus on effectiveness. BMJ Open, 2022. 12(8): p. e059606.
58.Koleva-Kolarova, R., et al., Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options. Appl Health Econ Health Policy, 2022. 20(4): p. 501-524.
59.Borry, P., et al., The challenges of the expanded availability of genomic information: an agenda-setting paper. J Community Genet, 2018. 9(2): p. 103-116.
60.Fan, C., C. Li, and X. Song, The relationship between health insurance and economic performance: an empirical study based on meta-analysis. Front Public Health, 2024. 12: p. 1365877.
61.Hussain, A., et al., Exploring sustainable healthcare: Innovations in health economics, social policy, and management. Heliyon, 2024. 10(13): p. e33186.
62.Brothers, K.B. and M.A. Rothstein, Ethical, legal and social implications of incorporating personalized medicine into healthcare. Per Med, 2015. 12(1): p. 43-51.
63.Clayton, E.W., et al., The law of genetic privacy: applications, implications, and limitations. J Law Biosci, 2019. 6(1): p. 1-36.

64.Chapman, C.R., et al., Genetic discrimination: emerging ethical challenges in the context of advancing technology. J Law Biosci, 2020. 7(1): p. lsz016.
65.Diaz, A., et al., Informed consent in dementia research: how Public Involvement can contribute to addressing “old” and “new” challenges. 2025. Volume 4 - 2025.
66.Coughlin, S.S., et al., Health Literacy, Social Determinants of Health, and Disease Prevention and Control. J Environ Health Sci, 2020. 6(1).
67.Chen, L. and M. Cheng Exploring Older Adults’ Perceived Affordability and Accessibility of the Healthcare System: Empirical Evidence from the Chinese Social Survey 2021. Healthcare, 2023. 11, DOI: 10.3390/healthcare11131818.
68.Clayton, E.W., et al., The law of genetic privacy: applications, implications, and limitations. Journal of Law and the Biosciences, 2019. 6(1): p. 1-36.
69.Pham, T., Ethical and legal considerations in healthcare AI: innovation and policy for safe and fair use. R Soc Open Sci, 2025. 12(5): p. 241873.
70.Alodhialah, A.M., A.A. Almutairi, and M. Almutairi, Ethical and Legal Challenges in Caring for Older Adults with Multimorbidities: Best Practices for Nurses. Healthcare (Basel), 2024. 12(16).
71.Horvat, M., I. Eržen, and D. Vrbnjak Barriers and Facilitators to Medication Adherence among the Vulnerable Elderly: A Focus Group Study. Healthcare, 2024. 12, DOI: 10.3390/ healthcare12171723.
72.Kamatham, P.T., et al., Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier. Ageing Research Reviews, 2024. 101: p. 102481.
73.Haleem, A., et al., Telemedicine for healthcare: Capabilities, features, barriers, and applications. Sens Int, 2021. 2: p. 100117.
74.Johnson, K.B., et al., Precision Medicine, AI, and the Future of Personalized Health Care. Clin Transl Sci, 2021. 14(1): p. 86-93.
75.Jones, C.H. and M. Dolsten, Healthcare on the brink: navigating the challenges of an aging society in the United States. NPJ Aging, 2024. 10(1): p. 22.
76.Jørgensen, J.T., Twenty Years with Personalized Medicine: Past, Present, and Future of Individualized Pharmacotherapy. Oncologist, 2019. 24(7): p. e432-e440.
77.Lauschke, V.M. and M. Ingelman-Sundberg, Emerging strategies to bridge the gap between pharmacogenomic research and its clinical implementation. NPJ Genom Med, 2020. 5: p. 9.
78.Zazzara, M.B., et al., Adverse drug reactions in older adults: a narrative review of the literature. Eur Geriatr Med, 2021. 12(3): p. 463-473.
79.Furrer, R. and C. Handschin, Biomarkers of aging: from molecules and surrogates to physiology and function. 2025. 105(3): p. 1609-1694.
80.Christensen, R., et al., Surrogate endpoints: a key concept in clinical epidemiology. J Clin Epidemiol, 2024. 167: p. 111242.
81.Wang, W.-H. and W.-S. Hsu Integrating Artificial Intelligence and Wearable IoT System in Long-Term Care Environments. Sensors, 2023. 23, DOI: 10.3390/s23135913.
82.Joseph, J., Algorithmic bias in public health AI: a silent threat to equity in low-resource settings. Front Public Health, 2025. 13: p. 1643180.
83.Kohn, D.B., Y.Y. Chen, and M.J. Spencer, Successes and challenges in clinical gene therapy. Gene Ther, 2023. 30(10-11): p. 738-746.
84.Rollinson, V., R. Turner, and M. Pirmohamed, Pharmacogenomics for Primary Care: An Overview. Genes (Basel), 2020. 11(11).
85.Ștefan, A.-M., et al. Empowering Healthcare: A Comprehensive Guide to Implementing a Robust Medical Information System—Components, Benefits, Objectives, Evaluation Criteria, and Seamless Deployment Strategies. Applied System Innovation, 2024. 7, DOI: 10.3390/asi7030051.